Skip to main content

Table 3 Prevalence of pulmonary hypertension according to treatment group

From: Venous thromboembolism and persistent pulmonary hypertension in cancer patients: a cross-sectional study

Treatment group

Pulmonary hypertension

1: No previous antineoplastic chemotherapy or chest radiotherapy (n = 345)

53 (15.4 %)

2: Previous chemotherapya without anthracyclines (n = 114)

18 (15.8 %)

3: Previous chemotherapy with anthracyclines (n = 79)

11 (13.9 %)

4: Previous chest radiotherapy from 1995 onwards (n = 74)

10 (13.5 %)

5: Pre-1995 chest radiotherapy (n = 23)

8 (34.8 %)

  1. aAlkylating agents, antimetabolites, microtubule-targeting agents, molecular-targeting agents. The treatment groups were not distinct from each other. Hence, no between-group comparisons could be made. The high proportion of patients with PH in group 5 probably relates to the high prevalence of atrial fibrillation and left heart disease among the 23 patients who had undergone pre-1995 radiotherapy (atrial fibrillation, 21.7 %; impaired left ventricular systolic function, 8.7 %; significant valvular heart disease, 34.8 %; left ventricular hypertrophy, 30.4 %)
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us